In vivo formation of a Schiff base of aminoguanidine with pyridoxal phosphate

Biochemical Pharmacology

Volumn 55, Issue 10, 1998, Pages 1667-1671

  Taguchi, Tadao ^a   Sugiura, Michiharu ^a   Hamada, Yoshiki ^a   Miwa, Ichitomo ^a  

^a MEIJO UNIVERSITY   (Japan)

Author keywords

Aminoguanidine; Diabetes; Glycation; Pyridoxal; Pyridoxal 5' phosphate; Pyridoxine

Indexed keywords

AMINOGUANIDINE; DRINKING WATER; PYRIDOXAL; PYRIDOXAL 5 PHOSPHATE; SCHIFF BASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; DIABETES MELLITUS; DRUG ANALYSIS; DRUG METABOLISM; DRUG TISSUE LEVEL; ENZYME ACTIVITY; KIDNEY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GUANIDINES; KIDNEY; LIVER; MICE; PYRIDOXAL PHOSPHATE; SCHIFF BASES;

EID: 0032524963     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(98)00010-0     Document Type: Article

References (18)

1. Bucala R, Vlassara H. Advanced glycosylation endproducts in diabetic renal disease Clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition . Blood Purif. 13:1995;160-170.
2. Kihara J, Schmelzer JD, Podusio JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA. 88:1991;6107-6111.
3. Hammes H-P, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia. 37:1994;32-35.
4. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes. 40:1991;1328-1334.
5. Edelstein D, Brownlee M. Mechanistic studies of advanced glycation end product. Inhibition by aminoguanidine. Diabetes. 41:1992;26-29.
6. Khatami M. Role of pyridoxal phosphate/pyridoxine in diabetes. Inhibition of nonenzymatic glycosylation. Ann NY Acad Sci. 585:1990;502-504.
7. Okada M, Ayabe Y. Effects of aminoguanidine and pyridoxal phosphate on glycation reaction of aspartate aminotransferase and serum albumin. J Nutr Sci Vitaminol (Tokyo). 41:1995;43-50.
8. 6 vitamers, especially pyridoxal 5′-phosphate. J Chromatogr A. 722:1996;295-301.
9. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia. 35:1992;946-950.
10. Tilton RG, Chang K, Hasan KS, Smith SR, Petrash JM, Misko TP, Moore WM, Currie MG, Corbett JA, McDaniel ML, Williamson JR. Prevention of diabetic vascular dysfunction by guanidines Inhibition of nitric oxide synthase versus advanced glycation end-product formation . Diabetes. 42:1993;221-232.
11. Soulis T, Cooper ME, Sastra S, Thallas V, Panagiotopoulos S, Bjerrum OJ, Jerums G. Relative contributions of advanced glycation and nitric oxide synthase inhibition to aminoguanidine-mediated renoprotection in diabetic rats. Diabetologia. 40:1997;1141-1151.
12. 6 group and related 3-hydroxypyridine derivatives. J Am Chem Soc. 77:1955;2431-2437.
13. Waymire KG, Mahuren JD, Jaje JM, Guilarte TR, Coburn SP, MacGregor GR. Mice lacking tissue non-specific alkaline phosphatase die from seizures due to defective metabolism of vitamin B-6. Nature Genet. 11:1995;45-51.
14. Khatami M, Suldan Z, David I, Li W, Rockey JH. Inhibitory effects of pyridoxal phosphate, ascorbate and aminoguanidine on nonenzymatic glycosylation. Life Sci. 43:1988;1725-1731.
15. Davis RE, Calder JS, Curnow DH. Serum pyridoxal and folate concentration in diabetics. Pathology. 8:1976;151-156.
16. Shepard DC, Hitz JB, Dain JA. Pyridoxal 5′-phosphate inhibits nonenzymatic glycosylation of proteins. Biochem Arch. 1:1985;143-151.
17. Booth AA, Khalifah RG, Hudson BG. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products Comparison with aminoguanidine . Biochem Biophys Res Commun. 220:1996;113-119.
18. 6 is a plausible molecular basis of the retinopathy of patients with diabetes mellitus. Biochem Biophys Res Commun. 179:1991;615-619.